focus -WSS

focus

author：fashion 2025-09-29 22:50:14 - browse：39225

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Churchill Downs extends trainer Bob Baffert's ban through 2024

WSS

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Behind warning on Apellis’s eye drug lies a conflict of interest

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Will biotech layoffs continue through 2023?

Timeline: Special counsel's probe into Trump's handling of classified documents

hotspot

focus

knowledge

Peter Hotez and the public health issue of online harassment

Biden announces an advanced cancer research initiative

Heart attack and stroke risk calculators need revising

Churchill Downs extends trainer Bob Baffert's ban through 2024

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Interest rates are at a 22

Heart attack and stroke risk calculators need revising

Marc Tessier

Duchenne breakthrough therapy leaves behind pioneering families

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

focus

EU climate chief is concerned over the expansion of the coal industry in China

The mammogram wars are not over

4 dead, 2 in stable condition in Philadelphia shooting: Police

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

Ford recalls 870K F

Timeline: Special counsel's probe into Trump's handling of classified documents

leisure time

entertainment

focus

knowledge